Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same

Patent metadata

Field	Value
Publication number	US-10870654-B2
Application number	US-201916356938-A
Country	US
Kind code	B2
Filing date	Mar 18, 2019
Priority date	Mar 8, 2013
Publication date	Dec 22, 2020
Grant date	Dec 22, 2020

Abstract

Compositions comprising hydrocodone benzoic acid enol ester to form novel prodrugs including hydrocodone benzoic acid enol ester salts, and various polymorphs. Also provided are processes for the preparation of hydrocodone benzoic acid enol ester salts, and various polymorphs.

First claim

The invention claimed is:

1. A process for the preparation of the following compound:

wherein the compound is a polymorphic form of hydrocodone benzoic acid enol ester, wherein the polymorphic form is Form I and Form I has an x-ray powder diffraction pattern comprising peaks at about the following 2θ values: 9.05, 12.32, 13.16, 14.94, and 18.57 comprising the steps of:
(a) preparing a mixture comprising hydrocodone free base and either benzoic anhydride or benzoyl chloride and,
(b) heating the mixture to a temperature in the range of about 80° C. to about 160° C.

2. The process of claim 1 further comprising the step of adding concentrated hydrochloric acid to the mixture to produce a compound having a following structure:

3. A pharmaceutical composition comprising a therapeutically effective amount of the compound prepared according to the process of claim 1 and a pharmaceutically acceptable excipient.

4. A pharmaceutical composition comprising a therapeutically effective amount of the compound prepared according to the process of claim 2 and a pharmaceutically acceptable excipient.

5. The process of claim 1 , wherein the mixture further comprises a suitable organic solvent.

6. The process of claim 5 , wherein the suitable organic solvent is selected from the group consisting of toluene, dimethylformamide, N-methyl-2-pyrrolidinone, and xylenes.

7. The process of claim 6 , wherein the toluene is substantially removed from the mixture via step (b).

8. The process of claim 1 , wherein the temperature of step (b) is in the range of about 126° C. to about 132° C.

9. The process of claim 1 , wherein the mixture further comprises a suitable base.

10. The process of claim 9 , wherein the suitable base is selected from the group consisting of pyridine, N,N-diisopropylethylamine (DIPEA), diazabicycloundecene (DBU), trimethylamine, and potassium benzoate.

11. The process of claim 1 , wherein Form I has an x-ray powder diffraction pattern further comprising peaks at about the following 2θ values: 6.16, 10.95, 11.91, 14.60, 17.04, 17.23, 17.80, 19.18, 20.66, 21.10, 22.15, 23.50, 26.07, and 28.39.

Assignees

• Kempharm Inc

Inventors

• Mickle Travis
• Guenther Sven
• Mickle Christal
• Chi Guochen
• Kanski Jaroslaw
• Martin Andrea K
• Bera Bindu

Classifications

• C07D489/04 Primary

  Salts; Organic complexes · CPC title

• C07D489/02

  with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone · CPC title

• C07B2200/13

  Crystalline forms, e.g. polymorphs · CPC title

• A61K31/485

  Morphinan derivatives, e.g. morphine, codeine · CPC title